Latest Manufacturing Operations News

PARKD Limited has raised $1 million to fund its East Coast expansion, secured a new prefabrication facility in NSW, and landed its first pilot project with McNab Group, marking a pivotal step in its national rollout.

EQ Resources Limited reported a robust Q1 FY2026 with soaring tungsten prices, operational upgrades, and significant capital raises to fuel mine expansions.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

Althea Group Holdings reported a resilient September quarter with $5.4 million in receipts despite a major strike in British Columbia, bolstered by a $2.53 million capital raise and expansion in the US THC beverage market.

Amaero Ltd reports a remarkable 445% increase in quarterly revenue driven by powder sales and manufacturing scale-up, alongside securing a US$22.8 million loan and exclusive supply agreements with key defense and aerospace players.

Dyno Nobel has finalised the sale of its Fertilisers Distribution business and is advancing strategic shifts including a new US TNT manufacturing partnership, underpinning a strong FY25 outlook.

Cann Group Limited has disclosed a late payment of over $1.37 million in interest and facility fees to National Australia Bank, which has issued a non-waiver letter but is holding off on immediate action. The company is actively negotiating financing arrangements and plans to update the market by the end of September 2025.

Mayne Pharma has publicly refuted recent media claims about plans to close its Salisbury manufacturing site, clarifying its position amid ongoing regulatory scrutiny of its Scheme transaction with Cosette.

Metal Powder Works Limited has completed a A$15 million institutional placement, strengthening its balance sheet to scale production and expand its market presence.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Magontec Limited reports a $5.25 million interim gross profit and a doubling of net assets per share to 84 cents, despite an underlying net loss. The company is banking on new Chinese supply partnerships and automation to restore profitability by FY 2026.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.